- Home
- STK vs CGEM Comparison
STK vs CGEM Comparison
Compare STK & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STK
- CGEM
- Stock Information
- Founded
- STK 2009
- CGEM 2016
- Country
- STK United States
- CGEM United States
- Employees
- STK N/A
- CGEM N/A
- Industry
- STK Investment Managers
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- STK Finance
- CGEM Health Care
- Exchange
- STK Nasdaq
- CGEM Nasdaq
- Market Cap
- STK 509.5M
- CGEM 530.0M
- IPO Year
- STK N/A
- CGEM 2021
- Fundamental
- Price
- STK $31.00
- CGEM $8.18
- Analyst Decision
- STK
- CGEM Strong Buy
- Analyst Count
- STK 0
- CGEM 6
- Target Price
- STK N/A
- CGEM $28.17
- AVG Volume (30 Days)
- STK 38.2K
- CGEM 324.2K
- Earning Date
- STK 01-01-0001
- CGEM 08-07-2025
- Dividend Yield
- STK 6.60%
- CGEM N/A
- EPS Growth
- STK N/A
- CGEM N/A
- EPS
- STK N/A
- CGEM N/A
- Revenue
- STK N/A
- CGEM N/A
- Revenue This Year
- STK N/A
- CGEM N/A
- Revenue Next Year
- STK N/A
- CGEM N/A
- P/E Ratio
- STK N/A
- CGEM N/A
- Revenue Growth
- STK N/A
- CGEM N/A
- 52 Week Low
- STK $24.95
- CGEM $6.85
- 52 Week High
- STK $34.31
- CGEM $20.96
- Technical
- Relative Strength Index (RSI)
- STK 64.34
- CGEM 54.88
- Support Level
- STK $30.42
- CGEM $7.42
- Resistance Level
- STK $30.97
- CGEM $8.70
- Average True Range (ATR)
- STK 0.28
- CGEM 0.38
- MACD
- STK -0.05
- CGEM 0.09
- Stochastic Oscillator
- STK 77.92
- CGEM 63.12
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.